Barricade Therapeutics

Barricade Therapeutics, Corp. is a Fort Worth, Texas oncology company developing first-in-class oral small-molecule therapies for genetically driven cancers. Its lead candidate, BT-1501, is an oral EBP inhibitor aimed at the genetic drivers of colorectal cancer progression, targeting APC-mutant advanced and metastatic disease. The program is IND-enabling, backed by roughly $17 million in non-dilutive funding from the Cancer Prevention and Research Institute of Texas, and is being advanced toward IND submission and first-in-human trials. The company was founded in 2017 and builds on its TASIN chemistry platform, with patent protection cited through 2039.

BT-1501 is a first-in-class oral EBP inhibitor that acts on the underlying genetic driver of APC-mutant colorectal cancer rather than through broad cytotoxic mechanisms, built on the company's proprietary TASIN small-molecule platform and funded largely by non-dilutive CPRIT grants.